Urocortins improve dystrophic skeletal muscle structure and function through both PKA- and epac-dependent pathways

American Journal of Pathology

Volumn 180, Issue 2, 2012, Pages 749-762

  Reutenauer Patte, Julie ^a   Boittin, Franois Xavier ^a   Patthey Vuadens, Ophlie ^a   Ruegg, Urs T ^a   Dorchies, Olivier M ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM INDEPENDENT PHOSPHOLIPASE A2; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; CREATINE KINASE; CYCLIC AMP; CYCLIC AMP BINDING PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; PROTEIN EPAC; STROMAL INTERACTION MOLECULE 1; UNCLASSIFIED DRUG; UROCORTIN I; UROCORTIN II;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DUCHENNE MUSCULAR DYSTROPHY; ENZYME ACTIVATION; ENZYME ACTIVITY; EX VIVO STUDY; FEMALE; FOOD INTAKE; MALE; MECHANICAL STRESS; MOUSE; MUSCLE CONTRACTION; MUSCLE INJURY; MUSCLE MASS; MUSCLE NECROSIS; MUSCLE RELAXATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE;

ACETYLCYSTEINE; ANIMALS; BREFELDIN A; CALCIUM; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ERYTHROMYCIN; GROUP VI PHOSPHOLIPASES A2; INJECTIONS, INTRADERMAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MUSCLE CONTRACTION; MUSCLE RELAXATION; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; PROTEIN KINASE INHIBITORS; PROTEIN SYNTHESIS INHIBITORS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; UROCORTINS;

EID: 84855999113     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2011.10.038     Document Type: Article

References (56)

1. J. Sabourin, C. Cognard, B. Constantin Regulation by scaffolding proteins of canonical transient receptor potential channels in striated muscle J Muscle Res Cell Motil 30 2009 289 297
2. F.W. Hopf, P.R. Turner, R.A. Steinhardt Calcium misregulation and the pathogenesis of muscular dystrophy Subcell Biochem 45 2007 429 464
3. D.G. Allen, N.P. Whitehead Duchenne muscular dystrophy: what causes the increased membrane permeability in skeletal muscle? Int J Biochem Cell Biol 43 2011 290 294
4. D.P. Millay, S.A. Goonasekera, M.A. Sargent, M. Maillet, B.J. Aronow, J.D. Molkentin Calcium influx is sufficient to induce muscular dystrophy through a TRPC-dependent mechanism Proc Natl Acad Sci U S A 106 2009 19023 19028
5. 2+ entry in skeletal muscle Pflgers Arch Eur J Physiol 460 2010 813 823
6. 2β: a view from a different perspective J Physiol 586 2008 3035 3042
7. 2+ entry in dystrophic skeletal muscle fibers J Cell Sci 119 2006 3733 3742
8. 2 activity in dystrophinopathies Neuromuscul Disord 5 1995 193 199
9. 2 and store-operated pathway in urocortin-induced vasodilatation of rat coronary artery Circ Res 101 2007 1194 1203
10. 2+ entry in dystrophic skeletal muscle fibers Biochem Biophys Res Commun 391 2010 401 406
11. 2: homeostatic phospholipases with significant potential as targets for novel therapeutics Curr Drug Targets 9 2008 683 697
12. A. Manzur, T. Kuntzer, M. Pike, A. Swan Glucocorticoid Corticosteroids for Duchenne Muscular Dystrophy (Review) The Cochrane Collaboration/John Wiley & Sons, Ltd 2008 1 93
13. L. Metzinger, A.C. Passaquin, W.J. Leijendekker, P. Poindron, U.T. Ruegg Modulation by prednisolone of calcium handling in skeletal muscle cells Br J Pharmacol 116 1995 2811 2816
14. E.M. Fekete, E.P. Zorrilla Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs Front Neuroendocrinol 28 2007 1 27
15. F.M. Dautzenberg, R.L. Hauger The CRF peptide family and their receptors: yet more partners discovered Trends Pharmacol Sci 23 2002 71 77
16. T. Kishimoto, R.V. Pearse, C.R. Lin, M.G. Rosenfeld A sauvagine/corticotropin-releasing factor receptor expressed in heart and skeletal muscle Proc Natl Acad Sci U S A 92 1995 1108 1112
17. S. Samuelsson, J.S. Lange, R.T. Hinkle, M. Tarnopolsky, R.J. Isfort Corticotropin-releasing factor 2 receptor localization in skeletal muscle J Histochem Cytochem 52 2004 967 977
18. J. de Rooij, F.J.T. Zwartkruis, M.H.G. Verheijen, R.H. Cool, S.M.B. Nijman, A. Wittinghofer, J.L. Bos Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP Nature 396 1998 474 477
19. S.S. Roscioni, C. Elzinga, M. Schmidt Epac: effectors and biological functions Naunyn Schmiedebergs Arch Pharmacol 377 2008 345 357
20. M. Gloerich, J.L. Bos Epac: defining a new mechanism for cAMP action Ann Rev Pharmacol Toxicol 50 2010 355 375
21. R.T. Hinkle, E. Donnelly, D.B. Cody, S. Samuelsson, J.S. Lange, M.B. Bauer, M. Tarnopolsky, R.J. Sheldon, S.C. Coste, E. Tobar, M.P. Stenzel-Poore, R.J. Isfort Activation of the CRF 2 receptor modulates skeletal muscle mass under physiological and pathological conditions Am J Physiol Endocrinol Metab 285 2003 E889 E898
22. R.T. Hinkle, E. Donnelly, D.B. Cody, M.B. Bauer, R.J. Sheldon, R.J. Isfort Corticotropin releasing factor 2 receptor agonists reduce the denervation-induced loss of rat skeletal muscle mass and force and increase non-atrophying skeletal muscle mass and force J Muscle Res Cell Motil 25 2005 539 547
23. R.T. Hinkle, F. Lefever, E. Dolan, D. Reichart, J. Dietrich, K. Gropp, R. Thacker, J. Demuth, P. Stevens, X. Qu, A. Varbanov, F. Wang, R.J. Isfort Corticotrophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx mice BMC Med 5 2007 18
24. J.E. Hall, J.J. Kaczor, B.P. Hettinga, R.J. Isfort, M.A. Tarnopolsky Effects of a CRF2R agonist and exercise on mdx and wildtype skeletal muscle Muscle Nerve 36 2007 336 341
25. M.D. Grounds, H.G. Radley, G.S. Lynch, K. Nagaraju, A. De Luca Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy Neurobiol Dis 31 2008 1 19
26. K. Nagaraju, R. Willmann TREAT-NMD Network and the Wellstone Muscular Dystrophy Cooperative Research Network: Developing standard procedures for murine and canine efficacy studies of DMD therapeutics: report of two expert workshops on "Pre-clinical testing for Duchenne dystrophy": Washington DC. October 27th-28th 2007and Zrich, June 30th-July 1st 2008 Neuromuscul Disord 19 2009 502 506
27. W.B. Im, S.F. Phelps, E.H. Copen, E.G. Adams, J.L. Slightom, J.S. Chamberlain Differential expression of dystrophin isoforms in strains of mdx mice with different mutations Hum Mol Genet 5 1996 1149 1153
28. J. Reutenauer, O.M. Dorchies, O. Patthey-Vuadens, G. Vuagniaux, U.T. Ruegg Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy Br J Pharmacol 155 2008 574 584
29. A. Passaquin, M. Renard, L. Kay, C. Challet, A. Mokhtarian, T. Wallimann, U.T. Ruegg Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice Neuromuscul Disord 12 2002 174 182
30. 2 augments spontaneous fatty acid release J Biol Chem 275 2000 18248 18258
31. O.M. Dorchies, S. Wagner, O. Vuadens, K. Waldhauser, T.M. Buetler, P. Kucera, U.T. Ruegg Green tea extract and its major polyphenol (-)-epigallocatechin gallate improve muscle function in a mouse model for Duchenne muscular dystrophy Am J Physiol Cell Physiol 290 2006 C616 C625
32. T.M. Buetler, M. Renard, E.A. Offord, H. Schneider, U.T. Ruegg Green tea extract decreases muscle necrosis in mdx mice and protects against reactive oxygen species Am J Clin Nutr 75 2002 749 753
33. H.G. Radley, A. De Luca, G.S. Lynch, M.D. Grounds Duchenne muscular dystrophy: focus on pharmaceutical and nutritional interventions Int J Biochem Cell Biol 39 2007 469 477
34. K. Patel, H. Amthor The function of myostatin and strategies of myostatin blockade: new hope for therapies aimed at promoting growth of skeletal muscle Neuromuscul Disord 15 2005 117 126
35. K. Patel, R. Macharia, H. Amthor Molecular mechanisms involving IGF-1 and myostatin to induce muscle hypertrophy as a therapeutic strategy for Duchenne muscular dystrophy Acta Myol 24 2005 230 241
36. N.D. Ullrich, M. Fanchaouy, K. Gusev, N. Shirokova, E. Niggli Hypersensitivity of excitation: contraction coupling in dystrophic cardiomyocytes Am J Physiol Heart Circ Physiol 297 2009 H1992 H2003
37. V. Nicolas-Metral, E. Raddatz, P. Kucera, U.T. Ruegg Mdx myotubes have normal excitability but show reduced contraction-relaxation dynamics J Muscle Res Cell Motil 22 2001 69 75
38. S. Okamoto, I. Ishikawa, K. Kimura, M. Saito Potent suppressive effects of urocortin on splenic lymphocyte activity in rats Neuroreport 9 1998 4035 4039
39. 2+-ATPase Biochemistry 47 2007 3 13
40. 2+ channels by dystrophin, the actin cytoskeleton, and cAMP-dependent protein kinase Proc Natl Acad Sci U S A 102 2005 4191 4196
41. J.-F. Rolland, A. De Luca, R. Burdi, F. Andreetta, P. Confalonieri, D. Conte Camerino Overactivity of exercise-sensitive cation channels and their impaired modulation by IGF-1 in mdx native muscle fibers: beneficial effect of pentoxifylline Neurobiol Dis 24 2006 466 474
42. 2+ store to the plasma membrane Nature 437 2005 902 905
43. 2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders Pharmacol Rev 58 2006 591 620
44. J.Y. Altarejos, M. Montminy CREB and the CRTC co-activators: sensors for hormonal and metabolic signals Nat Rev Mol Cell Biol 12 2011 141 151
45. R. Berdeaux, N. Goebel, L. Banaszynski, H. Takemori, T. Wandless, G.D. Shelton, M. Montminy SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes Nat Med 13 2007 597 603
46. R. Stewart, L. Flechner, M. Montminy, R. Berdeaux CREB is activated by muscle injury and promotes muscle regeneration PLoS One 6 2011 e24714
47. C. Reggiani, T. Kronnie RyR isoforms and fibre type-specific expression of proteins controlling intracellular calcium concentration in skeletal muscles J Muscle Res Cell Motil 27 2006 327 335
48. M. Mtrich, M. Berthouze, E. Morel, B. Crozatier, A.M. Gomez, F. Lezoualc'h Role of the cAMP-binding protein Epac in cardiovascular physiology and pathophysiology Pflgers Arch 459 2010 535 546
49. S.M. Davidson, A.E. Rybka, P.A. Townsend The powerful cardioprotective effects of urocortin and the corticotropin releasing hormone (CRH) family Biochem Pharmacol 77 2009 141 150
50. T.I. Emeto, J.V. Moxon, C. Rush, L. Woodward, J. Golledge Relevance of urocortins to cardiovascular disease J Mol Cell Cardiol 51 2011 299 307
51. A.W. Mazur, F. Wang, M. Tscheiner, E. Donnelly, R.J. Isfort Sauvagine analogs selective for corticotropin releasing factor 2 receptor: effect of substitutions at positions 35 and 39 on CRF2R selectivity Peptides 26 2005 887 891
52. R. Burdi, J.-F. Rolland, B. Fraysse, K. Litvinova, A. Cozzoli, V. Giannuzzi, A. Liantonio, G.M. Camerino, V. Sblendorio, R.F. Capogrosso, B. Palmieri, F. Andreetta, P. Confalonieri, L. De Benedictis, M. Montagnani, A. De Luca Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: outcome of a large array of in vivo and ex vivo tests J Appl Physiol 106 2009 1311 1324
53. A. Zimmerman, P.R. Clemens, C. Tesi-Rocha, A. Connolly, S.T. Iannaccone, N. Kuntz, A. Arrieta, L. Hache, E. Henricson, F. Hu, J. Mayhew, D.M. Escolar Liquid formulation of pentoxifylline is a poorly tolerated treatment for Duchenne dystrophy Muscle Nerve 44 2011 170 173
54. 2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses Br J Pharmacol 147 2006 587 595
55. L.J. Harcourt, J.D. Schertzer, J.G. Ryall, G.S. Lynch Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue Neuromuscul Disord 17 2007 47 55
56. A. Chen, J. Vaughan, W.W. Vale Glucocorticoids regulate the expression of the mouse urocortin II gene: a putative connection between the corticotropin-releasing factor receptor pathways Mol Endocrinol 17 2003 1622 1639